Media stories about Cambrex (NYSE:CBM) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cambrex earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.2591189743929 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Cambrex (NYSE:CBM) traded down $3.70 on Thursday, reaching $49.30. 611,713 shares of the company’s stock traded hands, compared to its average volume of 319,500. The stock has a market capitalization of $1,730.00, a P/E ratio of 16.33, a price-to-earnings-growth ratio of 1.24 and a beta of 2.38. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.

Cambrex (NYSE:CBM) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.12 by $0.15. The business had revenue of $182.28 million for the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company’s revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $1.23 earnings per share. analysts forecast that Cambrex will post 2.97 earnings per share for the current year.

CBM has been the topic of several analyst reports. Craig Hallum restated a “buy” rating and set a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. Zacks Investment Research upgraded shares of Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $60.00.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with's FREE daily email newsletter.